AstraZeneca, Isis unite to develop antisense cancer drugs

12/12/2012 | Reuters · Genetic Engineering & Biotechnology News

Isis Pharmaceuticals and AstraZeneca agreed to jointly discover and develop antisense treatments against five cancer targets. The agreement also covers rights to develop and market Isis' experimental drug ISIS-STAT3Rx, which is in Phase I development for patients with advanced lymphomas. The deal entitles Isis to $31 million upfront and near-term fees, plus potential licensing and milestone payments and sales royalties.

View Full Article in:

Reuters · Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President, Science and Regulatory Affairs
American Beverage Association
Washington, DC
Senior Manager of Medical Management
Network Health
Medford, MA
MEDICAL SCIENCE LIAISON - 14000002RO
Abbott
Columbus, OH
Manager, Medical Management
Network Health
Medford, MA
Executive Medical Director
Aspirus Network Inc
Wausau, WI